Need for Targeted Therapies, and Increasing Collaborations to Drive Global Companion Diagnostics Market: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit According to study, “Global Companion Diagnostics Market- Technologies, Market share and Industry Forecast to 2024” the major companies that are currently operating in the global companion diagnostics market are F. Hoffmann La Roche AG,Agilent Technologies, Inc., Qiagen N.V., Thermo Fisher Scientific Inc.,Abbott Laboratories Inc.,Myriad Genetics Inc., Danaher Corporation, Protagen Diagnostics, Amgen, AbbVie Inc., Acumen Pharmaceuticals, Inc., Celldex Therapeutics, Inc., OvaGene Oncology Inc., Oxford Cancer Biomarkers Ltd., Clovis Oncology, Inc., Eli Lilly, Adaptimmune Therapeutics plcAlmac Group, Sysmex Corporation, Genomic Health Inc., Ventana Medical Systems Inc., Leica BiosystemsNussloch GmbH, BioMerieux SA, GE Healthcare Ltd., Life Technologies Corporation, Illumina Inc., Arup Laboratories Inc. A companion diagnostic is a diagnostic test, which is used as a companion to a therapeutic drug to establish applicability to a particular person. It is also known as pharmacogenetic tests, which is developed based on companion bio markers. It prospectively helps predict likely response or severe toxicity. These are in vitro clinical laboratory assays, which is designed to predict the efficacy of a targeted cancer therapy through assessment of one or more bio markers for defining a drug (effective and non-effective). Some of the major sources of funding for companion diagnostics are the corporate debt, venture capital, follow-on public offerings of equity, initial public offerings of equity and corporate spin offs, which includes both public and private sources. On the basis of the indication, global companion diagnostics market is segmented into cardiovascular conditions, oncology, inflammation, central nervous system indications and virology. On the basis of technology, market is segmented into in-situ hybridization, immune-histo-chemistry, next-generation sequencing, polymerase chain reaction and molecular diagnostics. Molecular diagnostics is the highest growing and maximum revenue generator product & service segment consist of reagents, assay kits and software & services On the basis of disease, the market is segmented into colorectal cancer, gastric cancer, genital cancer, melanoma cancer, breast cancer and lung cancer. On the basis of product & services, the market is segmented into reagents, assay kits and software & services. On the basis of end user, the market is segmented into reference laboratories and pharmaceutical & biopharmaceutical companies. The market has witnessed significant rise due to the increase in patient base for infectious diseases & cancer globally, growing demand for companion diagnostics, high adoption of companion diagnostics and emerging applications of companion diagnostics. Some of the other key driving factors are rising cancer incidence across the globe, improved regulatory guidelines, need for targeted therapies, increasing collaborations and partnerships for test development. Apart from drivers some of the major challenges are lack of awareness, lack of skilled professionals and logistic issues have increased significantly in order to develop drug and companion diagnostics together. In addition, some drugs therapies are Camptosar, Gleevec, Herceptin, Erbitux, Iressa, Keytruda, Lynparza, Mekinist, Rubraca, Tagrisso, Tarceva, Venclexta, Xalkori, Zelboraf, Purinethol and Nolvaldex. North American region holds the largest share in companion diagnostics market, due to the technological advancement. The Asia Pacific market is expected to grow at the high CAGR between 2017 and 2024. The primary forces driving growth of the market are the growing prevalence diseases like cancer and neurology diseases, increasing number of hospitals and diagnostics laboratories created huge opportunity.The global companion diagnostics market is expected to grow at a CAGR of over 20.1% during the period of 2017-2024. Moreover, the closely associated pharmacodiagnostics IVD (in vitro diagnostic device) market is expected to grow annually by 20%. For more information on the research report, refer to below link: Global Companion Diagnostics Market Related Reports: https://www.kenresearch.com/healthcare/diagnostics/companion-diagnostics-market/173221-91.html https://www.kenresearch.com/healthcare/general-healthcare/india-genomics-molecular-diagnostics-market-research-report/524-91.html Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications sales@kenresearch.com +91-9015378249 Tags: companion diagnostics Industry Research Reports, companion diagnostics Industrys, companion diagnostics Market Sales, Global companion diagnostics market, Global companion diagnostics Market Application, Global companion diagnostics Market Forecast, Global companion diagnostics Market Growth, Global companion diagnostics Market Key Players & Key Products., Global companion diagnostics Market Major Players, Global companion diagnostics Market Overview, Global companion diagnostics Market Research Report, Global companion diagnostics Market Revenue, Global companion diagnostics Market Scope, Global companion diagnostics Market Segmentation, Global companion diagnostics Market share, Global companion diagnostics Market Size, Global companion diagnostics Market Trends, Global companion diagnostics Market Value